Regeneron Pharmaceuticals (REGN) reported its second-quarter financial results. The company posted earnings of $2.82 per share, beating consensus forecast by 17 cents. The company's revenue for the quarter was $1.21 billion, up 21.2% on a year-over-year basis. Revenue missed consensus forecast by $30 million. For 2016, REGN expects EYLEA sales growth to be between 20% and 25%.